295 related articles for article (PubMed ID: 25832688)
1. Phase 1/2 trials of Temozolomide, Motexafin Gadolinium, and 60-Gy fractionated radiation for newly diagnosed supratentorial glioblastoma multiforme: final results of RTOG 0513.
Brachman DG; Pugh SL; Ashby LS; Thomas TA; Dunbar EM; Narayan S; Robins HI; Bovi JA; Rockhill JK; Won M; Curran WP
Int J Radiat Oncol Biol Phys; 2015 Apr; 91(5):961-7. PubMed ID: 25832688
[TBL] [Abstract][Full Text] [Related]
2. Phase I study of hypofractionated intensity modulated radiation therapy with concurrent and adjuvant temozolomide in patients with glioblastoma multiforme.
Jastaniyah N; Murtha A; Pervez N; Le D; Roa W; Patel S; Mackenzie M; Fulton D; Field C; Ghosh S; Fallone G; Abdulkarim B
Radiat Oncol; 2013 Feb; 8():38. PubMed ID: 23425509
[TBL] [Abstract][Full Text] [Related]
3. Phase I trial of hypofractionated intensity-modulated radiotherapy with temozolomide chemotherapy for patients with newly diagnosed glioblastoma multiforme.
Chen C; Damek D; Gaspar LE; Waziri A; Lillehei K; Kleinschmidt-DeMasters BK; Robischon M; Stuhr K; Rusthoven KE; Kavanagh BD
Int J Radiat Oncol Biol Phys; 2011 Nov; 81(4):1066-74. PubMed ID: 20932651
[TBL] [Abstract][Full Text] [Related]
4. A Phase 2 Study of Concurrent Radiation Therapy, Temozolomide, and the Histone Deacetylase Inhibitor Valproic Acid for Patients With Glioblastoma.
Krauze AV; Myrehaug SD; Chang MG; Holdford DJ; Smith S; Shih J; Tofilon PJ; Fine HA; Camphausen K
Int J Radiat Oncol Biol Phys; 2015 Aug; 92(5):986-992. PubMed ID: 26194676
[TBL] [Abstract][Full Text] [Related]
5. Nimotuzumab, a humanized monoclonal antibody specific for the EGFR, in combination with temozolomide and radiation therapy for newly diagnosed glioblastoma multiforme: First results in Chinese patients.
Wang Y; Pan L; Sheng XF; Chen S; Dai JZ
Asia Pac J Clin Oncol; 2016 Mar; 12(1):e23-9. PubMed ID: 24571331
[TBL] [Abstract][Full Text] [Related]
6. Phase I/IIa trial of fractionated radiotherapy, temozolomide, and autologous formalin-fixed tumor vaccine for newly diagnosed glioblastoma.
Ishikawa E; Muragaki Y; Yamamoto T; Maruyama T; Tsuboi K; Ikuta S; Hashimoto K; Uemae Y; Ishihara T; Matsuda M; Matsutani M; Karasawa K; Nakazato Y; Abe T; Ohno T; Matsumura A
J Neurosurg; 2014 Sep; 121(3):543-53. PubMed ID: 24995786
[TBL] [Abstract][Full Text] [Related]
7. Phase II study of short-course radiotherapy plus concomitant and adjuvant temozolomide in elderly patients with glioblastoma.
Minniti G; Lanzetta G; Scaringi C; Caporello P; Salvati M; Arcella A; De Sanctis V; Giangaspero F; Enrici RM
Int J Radiat Oncol Biol Phys; 2012 May; 83(1):93-9. PubMed ID: 22079725
[TBL] [Abstract][Full Text] [Related]
8. Hypofractionated intensity modulated radiotherapy with temozolomide in newly diagnosed glioblastoma multiforme.
Ammirati M; Chotai S; Newton H; Lamki T; Wei L; Grecula J
J Clin Neurosci; 2014 Apr; 21(4):633-7. PubMed ID: 24380758
[TBL] [Abstract][Full Text] [Related]
9. Phase II trial of hypofractionated IMRT with temozolomide for patients with newly diagnosed glioblastoma multiforme.
Reddy K; Damek D; Gaspar LE; Ney D; Waziri A; Lillehei K; Stuhr K; Kavanagh BD; Chen C
Int J Radiat Oncol Biol Phys; 2012 Nov; 84(3):655-60. PubMed ID: 22483738
[TBL] [Abstract][Full Text] [Related]
10. Phase I/IIa study of cilengitide and temozolomide with concomitant radiotherapy followed by cilengitide and temozolomide maintenance therapy in patients with newly diagnosed glioblastoma.
Stupp R; Hegi ME; Neyns B; Goldbrunner R; Schlegel U; Clement PM; Grabenbauer GG; Ochsenbein AF; Simon M; Dietrich PY; Pietsch T; Hicking C; Tonn JC; Diserens AC; Pica A; Hermisson M; Krueger S; Picard M; Weller M
J Clin Oncol; 2010 Jun; 28(16):2712-8. PubMed ID: 20439646
[TBL] [Abstract][Full Text] [Related]
11. Phase I clinical trial assessing temozolomide and tamoxifen with concomitant radiotherapy for treatment of high-grade glioma.
Patel S; DiBiase S; Meisenberg B; Flannery T; Patel A; Dhople A; Cheston S; Amin P
Int J Radiat Oncol Biol Phys; 2012 Feb; 82(2):739-42. PubMed ID: 21353747
[TBL] [Abstract][Full Text] [Related]
12. Retrospective comparison of standard and escalated doses of radiotherapy in newly diagnosed glioblastoma patients treated with concurrent and adjuvant temozolomide.
Guler OC; Yıldırım BA; Önal C; Topkan E
Indian J Cancer; 2019; 56(1):59-64. PubMed ID: 30950447
[TBL] [Abstract][Full Text] [Related]
13. Concurrent temozolomide and dose-escalated intensity-modulated radiation therapy in newly diagnosed glioblastoma.
Tsien CI; Brown D; Normolle D; Schipper M; Piert M; Junck L; Heth J; Gomez-Hassan D; Ten Haken RK; Chenevert T; Cao Y; Lawrence T
Clin Cancer Res; 2012 Jan; 18(1):273-9. PubMed ID: 22065084
[TBL] [Abstract][Full Text] [Related]
14. Phase 2 Study of Bortezomib Combined With Temozolomide and Regional Radiation Therapy for Upfront Treatment of Patients With Newly Diagnosed Glioblastoma Multiforme: Safety and Efficacy Assessment.
Kong XT; Nguyen NT; Choi YJ; Zhang G; Nguyen HN; Filka E; Green S; Yong WH; Liau LM; Green RM; Kaprealian T; Pope WB; Nghiemphu PL; Cloughesy T; Lassman A; Lai A
Int J Radiat Oncol Biol Phys; 2018 Apr; 100(5):1195-1203. PubMed ID: 29722661
[TBL] [Abstract][Full Text] [Related]
15. Gliadel wafer implantation combined with standard radiotherapy and concurrent followed by adjuvant temozolomide for treatment of newly diagnosed high-grade glioma: a systematic literature review.
Ashby LS; Smith KA; Stea B
World J Surg Oncol; 2016 Aug; 14(1):225. PubMed ID: 27557526
[TBL] [Abstract][Full Text] [Related]
16. Dexamethasone administration during definitive radiation and temozolomide renders a poor prognosis in a retrospective analysis of newly diagnosed glioblastoma patients.
Shields LB; Shelton BJ; Shearer AJ; Chen L; Sun DA; Parsons S; Bourne TD; LaRocca R; Spalding AC
Radiat Oncol; 2015 Oct; 10():222. PubMed ID: 26520780
[TBL] [Abstract][Full Text] [Related]
17. Concurrent Chemoradiotherapy with Temozolomide Followed by Adjuvant Temozolomide for Newly Diagnosed Glioblastoma Patients: A Retrospective Multicenter Observation Study in Korea.
Kim BS; Seol HJ; Nam DH; Park CK; Kim IH; Kim TM; Kim JH; Cho YH; Yoon SM; Chang JH; Kang SG; Kim EH; Suh CO; Jung TY; Lee KH; Kim CY; Kim IA; Hong CK; Yoo H; Kim JH; Kang SH; Kang MK; Kim EY; Kim SH; Chung DS; Hwang SC; Song JH; Cho SJ; Lee SI; Lee YS; Ahn KJ; Kim SH; Lim DH; Gwak HS; Lee SH; Hong YK
Cancer Res Treat; 2017 Jan; 49(1):193-203. PubMed ID: 27384161
[TBL] [Abstract][Full Text] [Related]
18. Trans sodium crocetinate with temozolomide and radiation therapy for glioblastoma multiforme.
Gainer JL; Sheehan JP; Larner JM; Jones DR
J Neurosurg; 2017 Feb; 126(2):460-466. PubMed ID: 27177177
[TBL] [Abstract][Full Text] [Related]
19. Patterns of recurrence and outcomes of glioblastoma multiforme treated with chemoradiation and adjuvant temozolomide.
Faustino AC; Viani GA; Hamamura AC
Clinics (Sao Paulo); 2020; 75():e1553. PubMed ID: 32935821
[TBL] [Abstract][Full Text] [Related]
20. Addition of bevacizumab to standard radiation therapy and daily temozolomide is associated with minimal toxicity in newly diagnosed glioblastoma multiforme.
Vredenburgh JJ; Desjardins A; Kirkpatrick JP; Reardon DA; Peters KB; Herndon JE; Marcello J; Bailey L; Threatt S; Sampson J; Friedman A; Friedman HS
Int J Radiat Oncol Biol Phys; 2012 Jan; 82(1):58-66. PubMed ID: 21036490
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]